title: Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor.
abstract: BACKGROUND
  Pityriasis (tinea) versicolor has a high tendency to recur after being treated successfully. Prophylactic treatment to reduce recurrence is needed.
  
  
  OBJECTIVE
  To determine whether recurrence of pityriasis versicolor could be prevented by prophylactic itraconazole treatment.
  
  
  METHODS
  Open treatment followed by a randomized, double-blind, placebo-controlled phase.
  
  
  METHODS
  Multinational outpatient centers.
  
  
  METHODS
  A total of 239 consecutive patients were included; 238 started open treatment. A total of 209 patients started prophylactic treatment: 106 in the itraconazole group and 103 in the placebo group.
  
  
  METHODS
  Open treatment: itraconazole, 200 mg once daily for 7 days. Prophylactic treatment: itraconazole, 200 mg, or placebo twice daily 1 day per month for 6 consecutive months.
  
  
  METHODS
  Mycological cure rates at the end of open treatment and at the end of prophylactic treatment.
  
  
  RESULTS
  Mycological cure at the end of open treatment was 92% (205/223). At the prophylactic treatment end point (6 months), mycological cure was 88% (90/102) in the itraconazole group and 57% (56/99) in the placebo group (P<.001). In open treatment, 11 patients were not able to be evaluated for efficacy. In prophylactic treatment, 4 patients in the itraconazole group and 4 in the placebo group were not able to be evaluated. Adverse events were reported during open treatment by 26 patients (11%) and during prophylactic treatment by 17 (16%) in the itraconazole group and 14 (14%) in the placebo group. No patients experienced any serious adverse events.
  
  
  CONCLUSIONS
  Prophylactic itraconazole treatment is efficacious for pityriasis versicolor after 6 months, as is itraconazole in the treatment of pityriasis versicolor.
authors.affiliation: Department of Dermatology, Sahlgrenska University Hospital, S-413 45 Gothenburg, Sweden. jan.faergemann@derm.gu.se
authors.forename: Jan
authors.initials: J
authors.lastname: Faergemann
authors.forename: A K
authors.initials: AK
authors.lastname: Gupta
authors.forename: A
authors.initials: A
authors.lastname: Al Mofadi
authors.forename: A
authors.initials: A
authors.lastname: Abanami
authors.forename: A Abu
authors.initials: AA
authors.lastname: Shareaah
authors.forename: Greet
authors.initials: G
authors.lastname: Marynissen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017964:Itraconazole / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D012680:Sensitivity and Specificity; D014010:Tinea Versicolor / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D017964:Itraconazole